

Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests

Name of Advisory Committee Member: Jean Grem, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: December 16, 2008

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: Discussion of Biologics License Application (BLA) 125084, trade name Erbitux (cetuximab), sponsored by ImClone Systems, Inc., and BLA 125147, trade name Vectibix (panitumumab), sponsored by Amgen, Inc., regarding types of studies and data needed to establish K-ras mutational status as predictive of response to drug therapy or as prognostic biomarker in colon cancer, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
	Eastern Oncology Cooperative Group	\$0 - \$50,000
	Cancer and Leukemia Group B	\$0 - \$50,000
	Eastern Oncology Cooperative Group	\$0 - \$50,000
	Eastern Oncology Cooperative Group	\$0 - \$50,000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

11/25/2008
Date